The Japanese Society for Pediatric Endocrinology
Bylaws Concerning Conflict of Interest Policy in Medical Research
Implemented Apr. 1, 2019
Partially revised Apr. 1,2021
Partially revised Jul. 10, 2021

Article 5 (About medical research and related organizations)"Medical research" is a basic and clinical study for humans carried out for the purposeof improving the prevention, the diagnosis and the treatment, the understanding of
etiological and pathological condition, and the quality of life of patients.
Medical research targeting humans includes research on human-derived samples
that can identify individuals and data that can identify individuals. Whether it
corresponds to specimens or data that can identify individuals is as specified “Ethics
Guidelines on Medical Research for Human” in the Ministry of Health, Labor andWelfare’s.
“Business enterprises, for profit corporate organizations, and commercial entities
related to medical research” are defined as follows.
(1) Sponsors of medical research, or organizations who jointly conduct clinicalresearch, regardless of whether funded or non-funded.
(2) Organizations sharing the rights including patent rights regarding treatment
methods, drugs and/or equipment that are evaluated in medical research.
(3) Organizations providing drugs and/or equipment for medical research gratis or at
an advantageous price.
(4) Organizations funding or contributing financially to medical research.
(5) Organizations providing unapproved drug and/or equipment for medical research.
(6) Sponsors of endowed departments.

Article 6 (Criteria for self-reported COI disclosure)
All COIs must be reported if the amount exceeds the criteria specified below.
(1) Employment or administrative position, or advisory role in business enterprises,for profit corporate organizations, or commercial entities that are related to clinicalresearch (hereafter referred to as “Commercial Entity”), if compensation from asingle Commercial Entity exceeds 1,000,000 yen per year.
(2) Stock ownership or options, if profit (total of dividend and gain on sales) of at least
1,000,000 yen from stocks of one Commercial Entity per year, or ownership of 5%
or more of total shares.
(3) Patent royalties from one Commercial Entity, if the royalty fee exceeds 1,000,000
yen per year.
(4) Honoraria (e.g. lecture fees) paid from one Commercial Entity, for the time and/or
labor of an investigator who attended or made presentations at meetings, if
exceeding 500,000 yen per year.
(5) Manuscript fees for promotional materials (e.g. brochures) paid by one
Commercial Entity, if exceeding 500,000 yen per year.
(6) Total amount that the recipient can practically use for research funds paid for
medical research (e.g. funded research, collaborative research) paid by one
Commercial Entity, if exceeding 1,000,000 yen per year.
(7) Total amount that the recipient can practically use for subsidy or donation to anindividual or a head of department to which the individual belongs received fromone Commercial Entity, if exceeding 1,000,000 yen per year.
(8) Endowed departments provided by a Commercial Entity, if the recipientparticipates in such a department. Note that the total amount of donations that therecipient can practically use more than 1,000,000 yen per year.
(9) Others including trips, travel, or gifts, which are not directly related to research,
provided by one Commercial Entity, if exceeding 50,000 yen per.